C4X Discovery Holdings PLC Publication of 2020 Annual Report (1541J)
18 December 2020 - 8:12PM
UK Regulatory
TIDMC4XD
RNS Number : 1541J
C4X Discovery Holdings PLC
18 December 2020
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
Publication of 2020 Annual Report
18 December 2020 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering Drug Discovery company, announces that its annual report
and accounts for the year ended 31 July 2020 has been published on
the Company's website and is available to download from:
www.c4xdiscovery.com .
- Ends -
Contacts
C4X Discovery Holdings
Mo Noonan, Communications +44 (0)787 6444977
Panmure Gordon (UK) Limited (NOMAD and
Broker)
Freddy Crossley, Emma Earl (Corporate
Finance) +44 (0)20 7886 2500
Rupert Dearden (Corporate Broking)
C4X Discovery Media - Consilium Strategic
Communications
Mary-Jane Elliott, Chris Gardner, Matthew
Neal +44 (0)203 709 5700
Notes to Editors:
About C4X Discovery
C4X Discovery (C4XD) aims to create the world's most productive
Drug Discovery engine by using cutting-edge technologies and
expertise to efficiently deliver best-in-class small-molecule
medicines to clinical partners for the benefit of patients. The
Company's business model focuses on replenishing big pharma
discovery pipelines and driving returns through revenue generating
pre-clinical licensing deals. In 2018, C4XD successfully
out-licensed a pre-clinical programme in addictive disorders to
Indivior in a deal worth up to $294m, which is now in a Phase I
clinical study.
C4XD has a state-of-the-art suite of proprietary technologies
across the Drug Discovery process and accesses further innovative
capabilities and expertise through its growing network of partners.
The Company is actively advancing its diverse pre-clinical
discovery portfolio which is focused on inflammation,
neurodegeneration and oncology (including immuno-oncology).
Opportunities to maximise value from the portfolio are proactively
driven by C4XD's commercial division. The Company is led by a
highly experienced management team and Board who have delivered
significant value creation within the healthcare sector.
For additional information please go to:
www.c4xdiscovery.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACSGCBDDGBBDGGI
(END) Dow Jones Newswires
December 18, 2020 04:12 ET (09:12 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Apr 2024 to May 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From May 2023 to May 2024